ArticleCureus2026
Mismatch Repair Protein Expression in Endometrial Intraepithelial Neoplasia and Endometrial Carcinoma: Experience From a Tertiary Care Hospital.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEndometrial carcinoma is the most common malignancy of the female genital tract, and endometrial intraepithelial neoplasia (EIN, also termed atypical endometrial hyperplasia) is its recognized precursor lesion. Mismatch repair (MMR) deficiency, identified through loss of MLH1, PMS2, MSH2, and MSH6 expression on immunohistochemistry (IHC), is an important molecular event in endometrial carcinogenesis with diagnostic, prognostic, and hereditary (Lynch syndrome) implications. Comparatively few studies have examined the frequency of MMR loss in EIN. This study evaluated the proportion and patterns of MMR protein loss in EIN and endometrial carcinoma, with descriptive assessment of MMR protein loss according to histopathological grade of endometrial carcinoma. METHODOLOGY: This cross-sectional study was conducted in a tertiary care hospital from August 2024 to December 2025 on 28 endometrial specimens (endometrial biopsies and hysterectomy specimens). These specimens were diagnosed histopathologically as EIN or endometrial carcinoma, collected retrospectively and prospectively using convenience sampling. Formalin-fixed, paraffin-embedded sections were stained with hematoxylin and eosin and evaluated. IHC for MLH1, MSH2, MSH6, and PMS2 was performed on all cases. Complete loss of nuclear staining for any MMR protein with intact internal controls was interpreted as MMR-deficient (dMMR); retained staining for all four proteins was interpreted as MMR-proficient (pMMR). Descriptive assessment of MMR protein loss according to histopathological grade of endometrial carcinoma was also performed.
resultsOf 28 cases, 16 (57.14%) were endometrioid endometrial carcinoma, and 12 (42.86%) were EIN. Patients' ages ranged from 34-68 years; EIN was most common in the sixth decade and carcinoma in the fifth. Among the 16 carcinomas, nine (56.25%) were International Federation of Gynecology and Obstetrics (FIGO) grade 1, six (37.50%) grade 2, and one (6.25%) grade 3. Only one carcinoma (6.25%) was dMMR, showing combined loss of MSH2 and MSH6, and this case was FIGO grade 2. Among the 12 EIN cases, only one (8.33%) was dMMR, showing combined loss of MLH1 and PMS2. All remaining cases in both groups were pMMR.
conclusionsMMR protein loss was infrequent in this cohort of EIN and endometrial carcinoma, consistent with the broader literature describing MMR deficiency as a relatively uncommon but clinically significant event across the endometrial hyperplasia-carcinoma sequence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.